03:15 PM - 03:30 PM

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities

Location: Le Meridian AL Khobar, Saudi Arabia

Social Share

× How can I help you?